BRPI0417803A - método de tratamento de rejeição de transplantes - Google Patents

método de tratamento de rejeição de transplantes

Info

Publication number
BRPI0417803A
BRPI0417803A BRPI0417803-3A BRPI0417803A BRPI0417803A BR PI0417803 A BRPI0417803 A BR PI0417803A BR PI0417803 A BRPI0417803 A BR PI0417803A BR PI0417803 A BRPI0417803 A BR PI0417803A
Authority
BR
Brazil
Prior art keywords
transplant rejection
treatment method
rejection treatment
administering
treating
Prior art date
Application number
BRPI0417803-3A
Other languages
English (en)
Inventor
Paul Steven Changelian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0417803A publication Critical patent/BRPI0417803A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"MéTODO DE TRATAMENTO DE REJEIçãO DE TRANSPLANTES". Método de tratamento ou prevenção da rejeição crónica ao transplante de órgãos compreendendo a administração de um composto da fórmula (I) na qual R¬ 1¬, R¬ 2¬ e R¬ 3¬ estão definidos como acima.
BRPI0417803-3A 2003-12-17 2004-12-06 método de tratamento de rejeição de transplantes BRPI0417803A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53118003P 2003-12-17 2003-12-17
PCT/IB2004/004034 WO2005060972A2 (en) 2003-12-17 2004-12-06 Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection

Publications (1)

Publication Number Publication Date
BRPI0417803A true BRPI0417803A (pt) 2007-04-10

Family

ID=34710208

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417803-3A BRPI0417803A (pt) 2003-12-17 2004-12-06 método de tratamento de rejeição de transplantes

Country Status (17)

Country Link
US (1) US20050159433A1 (pt)
EP (1) EP1734967A2 (pt)
JP (1) JP2007514729A (pt)
KR (1) KR20060096153A (pt)
CN (1) CN1893952A (pt)
AU (1) AU2004305317A1 (pt)
BR (1) BRPI0417803A (pt)
CA (1) CA2549485A1 (pt)
CO (1) CO5700767A2 (pt)
IL (1) IL175812A0 (pt)
MX (1) MXPA06007002A (pt)
NO (1) NO20062292L (pt)
RU (1) RU2006120956A (pt)
SG (1) SG133602A1 (pt)
TW (1) TW200529853A (pt)
WO (1) WO2005060972A2 (pt)
ZA (1) ZA200604888B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
BR0316487A (pt) 2002-11-26 2005-10-11 Pfizer Prod Inc Método todo de tratamento da rejeição de transplantes
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
ES2575797T3 (es) 2007-06-13 2016-07-01 Incyte Holdings Corporation Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CN102459270B (zh) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102574857B (zh) 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
RU2013136906A (ru) 2011-01-07 2015-02-20 Лео Фарма А/С Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение
BR112013020798B1 (pt) 2011-02-18 2022-03-15 Incyte Corporation Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
CN103896826B (zh) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法
WO2014102826A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN104059016A (zh) * 2014-06-20 2014-09-24 湖南天地恒一制药有限公司 制备托法替布的中间体及所述中间体的制备方法
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53782A (en) * 1866-04-10 Improvement in nut-machines
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
BR0316487A (pt) * 2002-11-26 2005-10-11 Pfizer Prod Inc Método todo de tratamento da rejeição de transplantes

Also Published As

Publication number Publication date
IL175812A0 (en) 2008-04-13
CO5700767A2 (es) 2006-11-30
NO20062292L (no) 2006-06-14
EP1734967A2 (en) 2006-12-27
ZA200604888B (en) 2007-11-28
CN1893952A (zh) 2007-01-10
AU2004305317A1 (en) 2005-07-07
MXPA06007002A (es) 2006-08-31
US20050159433A1 (en) 2005-07-21
JP2007514729A (ja) 2007-06-07
WO2005060972A3 (en) 2005-10-20
TW200529853A (en) 2005-09-16
RU2006120956A (ru) 2008-01-27
CA2549485A1 (en) 2005-07-07
WO2005060972A2 (en) 2005-07-07
SG133602A1 (en) 2007-07-30
KR20060096153A (ko) 2006-09-07

Similar Documents

Publication Publication Date Title
BRPI0417803A (pt) método de tratamento de rejeição de transplantes
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
BRPI0416909A (pt) método de tratamento de aterosclerose
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0413746A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
BR0316107A (pt) N-alquil-4-metilenoamino-3-hidróxi-2-piridonas como antimicrobianos
DK1755576T3 (da) Antimikrobielle sammensætning og fremgansmåde til anvendlese deraf
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
BRPI0413740A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
EA200601123A1 (ru) Фармацевтические композиции и способы лечения инсулином
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
BRPI0414701A (pt) uso de um composto de vitamina d, método de prevenção ou tratamnento de disfunção de bexiga em um paciente, composto de vitamina d, e, kit
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
BR0316245A (pt) Atividade antimicrobiana de espécie de oxigênio reativo produtora de anticorpos
ATE482705T1 (de) Antibakterielle behandlung von osteoarthritis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.